Facets of shared decision-making on drug treatment for adults with an eating disorder

Autor:	Jessica Bentley, Katie Au, Nicole Lichtblau, Hubertus Himmerich, Clare Brennan
Rok vydání:	2019
Předmět:	medicine.medical_specialty Anorexia Nervosa Narcotic Antagonists bulimia nervosa eating disorders Anorexia nervosa psychopharmacological treatment anorexia nervosa 03 medical and health sciences Drug treatment 0302 clinical medicine Dopamine Uptake Inhibitors Drug Therapy Pro re nata Binge-eating disorder Acute care binge eating disorder Excitatory Amino Acid Agonists medicine Humans Bulimia Nervosa Intensive care medicine Shared decision-making Cannabinoid Receptor Agonists Bulimia nervosa business.industry medicine.disease 030227 psychiatry Psychiatry and Mental health Eating disorders Impaired insight business Decision Making Shared Binge-Eating Disorder Selective Serotonin Reuptake Inhibitors 030217 neurology & neurosurgery Antipsychotic Agents
Zdroj:	Himmerich, H, Bentley, J, Lichtblau, N, Brennan, C & Au, K 2019, ' Facets of shared decision making on drug treatment for adults with an eating disorder ', International Review of Psychiatry, vol. 31, no. 4, pp. 332-346 . https://doi.org/10.1080/09540261.2019.1571995
ISSN:	1369-1627 0954-0261
DOI:	10.1080/09540261.2019.1571995
Popis:	Shared decision making (SDM) means that clinicians and the patient make decisions about the treatment together. Regarding drug treatment in eating disorders (EDs), such decisions may include psychopharmacological treatment for the ED itself, medications for potential co-morbid psychiatric disorders, pharmacological strategies to alleviate the health consequences of an ED or “pro re nata” (PRN) medication which is given in acute care when required.Decisions regarding drug treatment in EDs should be specific in terms of the active pharmacological substance, its dose, its route of administration and the duration of treatment. Decisions should be made with regard to the specific health risks of patients with EDs and the entire treatment approach, and should take alternative measures, additional therapies and specific combinations of therapies into account.The differences in the expectations of patients, carers and clinicians towards drug treatment, the lack of specific suggestions in clinical practice guidelines and the lack of approved psychopharmacological treatment options make SDM necessary, but also a challenge. However, SDM may be limited due to the patient’s impaired insight or limited capacity due to the ED. Thus, the legal framework must be taken into consideration.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49c6bd019c2868763cc7c8aadc8ba1e9 https://doi.org/10.1080/09540261.2019.1571995 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.